Fund+ leads €38m series-B for Indigo Diabetes

Ackermans & van Haaren, Imec Xpand, Capricorn Digital Growth Fund, QBICII and Titan Baratto also participated in the round.

Jan Van den Bossche, a partner at Fund+, will join the board of the company.

The fresh capital will be used to accelerate the development of the company's product into clinical development.

Previous funding
In December 2016, Thuja Capital and PMV led a €7m series-A investment round for Indigo. The round also saw participation from Sensinnovat, Parana Management Corp, Qbic Arkiv Fund, Fidimec, Sofi, Manuardeo and Capricorn ICT Arkiv.

Company
Founded in 2016 and headquartered in Ghent, Indigo is a medical device technology company that develops a subcutaneous sensor for people living with diabetes to address their need for accurate glucose monitoring.

People
Fund+ – Jan Van den Bossche (partner); Chris Buyse (managing partner, executive board member).
Indigo Diabetes – Danaë Delbeke (CEO, founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Benelux
• Expansion
• Belgium
• Venture